Last reviewed · How we verify
Rovi Pharmaceuticals Laboratories — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
1 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ISM® | ISM® | marketed | Other | |||
| Clexane | Clexane | marketed | Other | |||
| Placebo of Risperidone ISM | Placebo of Risperidone ISM | phase 3 | Psychiatry |
Therapeutic area mix
- Other · 2
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Rovi Pharmaceuticals Laboratories:
- Rovi Pharmaceuticals Laboratories pipeline updates — RSS
- Rovi Pharmaceuticals Laboratories pipeline updates — Atom
- Rovi Pharmaceuticals Laboratories pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rovi Pharmaceuticals Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rovi-pharmaceuticals-laboratories. Accessed 2026-05-17.